Clinical Use of Antibodies: Tumours, infection, infarction, rejection and in the diagnosis of AIDS (Developments in Nuclear Medicine, 19)

It was at Frankfurt/Mainin 1899 that Paul Ehrlich first expounded his famous "site-chain theory" -which described the basic immunological principal of antibody-antigen interactio- on the occasion of the opening of the Institute for Experimental Therapeutics (which was later named after him). Nearly 100 years have passed since, and in retrospect it can be said that the "Ehrlich Era" (first steps in immunology "Magic Bullet" concept) and the "Behring Era" (detection of antibodies and serum therapy) formed the essential basis in the development of immunology. Niels K. Jerne, the former director of the Paul Ehrlich Institute in Frankfurt/Main received, together with Georges Kohler and Cesar Milstein, the Nobel Prize in Medicine 1984. These late successors of Ehrlich and Behring first described the hybridoma technology (in 1975) which enabled one of the most important and revolutionary technological innovations in the field of immunology -the production of monoclonal antibodies. It happens that, the time of the publication of this book, just a decade has passed since the first use of radiolabelled monoclonal antibodies in man (by the Lausanne Group). Over these 10 years a tremendous progress has taken place in the field of immunoscintigraphy:A large panel of highly specific monoclonal antibodies against tumour-associated antigens as well as normal cell compounds have been developed. Enormous progress has been made in the field of radiolabelling -from iodine-131 to technetium-99mor even positron-emittingradionuclides, e. g. iodine-124. Front Matter....Pages i-x Advances in Cancer Imaging and Therapy with Radiolabelled Antibodies....Pages 1-13 Evaluation of the Diagnostic Utility of Immunoscintigraphy in Oncology....Pages 15-30 The Quality Control and Clinical Testing of Radiolabelled Antibodies....Pages 31-35 Clinical Utility of Radiolabelled Monoclonal Antibodies in the Management of Gastrointestinal Cancer....Pages 37-44 Use of 123-I Radiolabelled F(AB’)2 Fragments of Anti-CEA Monoclonal Antibody for the Detection of Primary and Metastatic Gastrointestinal Carcinomas....Pages 45-53 Bispecific Monoclonal Antibodies for two Phase Radioimmunotherapy....Pages 55-68 Antimyosin Antibody Imaging in Myocardial Infarction....Pages 69-83 Antimyosin Based Radioimmunodetection of Myocarditis Cardiomyopathy and Cardiac Transplant Rejection....Pages 85-89 Recent Advances in the Use of Radiolabelled Monoclonal Antibodies in the Management of Ovarian Cancer....Pages 91-110 Monoclonal Antibodies for Cell Labelling with Particular Reference to Thrombus Imaging....Pages 111-120 The Role of Nuclear Medicine in the Evaluation of the Patient with Acquired Immune Deficiency Syndrome (AIDS)....Pages 121-144 Detection of Inflammation/Infection using Radiolabelled Anti-Granulocyte Antibodies: Possibilities and Limitations....Pages 145-150 A New Marker for the Detection of Adenocarcinomas by Radioimmunoscintigraphy....Pages 151-168 New Developments in the Diagnosis of Aids and Strategies for Therapy....Pages 169-181 Back Matter....Pages 183-185